- Home
- SVII vs LCTX Comparison
SVII vs LCTX Comparison
Compare SVII & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- LCTX
- Stock Information
- Founded
- SVII 2021
- LCTX 1990
- Country
- SVII United States
- LCTX United States
- Employees
- SVII N/A
- LCTX N/A
- Industry
- SVII Blank Checks
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVII Finance
- LCTX Health Care
- Exchange
- SVII Nasdaq
- LCTX Nasdaq
- Market Cap
- SVII 116.6M
- LCTX 107.3M
- IPO Year
- SVII 2022
- LCTX N/A
- Fundamental
- Price
- SVII $11.70
- LCTX $0.93
- Analyst Decision
- SVII
- LCTX Strong Buy
- Analyst Count
- SVII 0
- LCTX 5
- Target Price
- SVII N/A
- LCTX $4.20
- AVG Volume (30 Days)
- SVII 4.7K
- LCTX 4.5M
- Earning Date
- SVII 01-01-0001
- LCTX 08-07-2025
- Dividend Yield
- SVII N/A
- LCTX N/A
- EPS Growth
- SVII N/A
- LCTX N/A
- EPS
- SVII 0.25
- LCTX N/A
- Revenue
- SVII N/A
- LCTX $9,557,000.00
- Revenue This Year
- SVII N/A
- LCTX N/A
- Revenue Next Year
- SVII N/A
- LCTX $232.66
- P/E Ratio
- SVII $47.38
- LCTX N/A
- Revenue Growth
- SVII N/A
- LCTX 19.42
- 52 Week Low
- SVII $11.06
- LCTX $0.37
- 52 Week High
- SVII $11.90
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- SVII 54.77
- LCTX 59.77
- Support Level
- SVII $11.50
- LCTX $0.87
- Resistance Level
- SVII $11.78
- LCTX $1.15
- Average True Range (ATR)
- SVII 0.07
- LCTX 0.11
- MACD
- SVII -0.00
- LCTX -0.00
- Stochastic Oscillator
- SVII 78.86
- LCTX 47.98
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.